O'Neil, Patrick M.

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 850

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 814

Weight loss with naltrexone sr/bupropion sr combination therapy as an adjunct to behavior modification: the COR-BMOD trial

Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity

Pharmacology and Obesity TreatmentEating Disorders and Behaviors

Cited by 558

A prospective study of holiday weight gain

Yanovski, J. A., Yanovski, S. Z., Sovik, K. N., Nguyen, T. T., O'Neil, P. M., & Sebring, N. G. (2000) · New England Journal of Medicine

Obesity, Physical Activity, DietNutrition, Health and Food Behavior

Cited by 334

Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial

Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research

Pharmacology and Obesity TreatmentEating Disorders and Behaviors

Cited by 315

Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study

Kaplan, L. M., Golden, A., Jinnett, K., Kolotkin, R. L., Kyle, T. K., Look, M., Nadglowski, J., O'Neil, P. M., Parry, T., Tomaszewski, K. J., et al. (2018) · Obesity

Obesity and Health PracticesObesity, Physical Activity, Diet

Cited by 312

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J. (1999) · The American Journal of Clinical Nutrition

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 287

Night eating syndrome: effects of brief relaxation training on stress, mood, hunger, and eating patterns

Pawlow, L. A., O'Neil, P. M., & Malcolm, R. J. (2003) · International Journal of Obesity

Eating Disorders and BehaviorsSleep and related disorders

Cited by 156

Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers

Fujioka, K., O'Neil, P. M., Davies, M., Greenway, F., C.W. Lau, D., Claudius, B., Skjøth, T. V., Bjørn Jensen, C., & P.H. Wilding, J. (2016) · Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 131

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials

O'Neil, P. M., Aroda, V. R., Astrup, A., Kushner, R., Lau, D. C. W., Wadden, T. A., Brett, J., Cancino, A., Wilding, J. P. H., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2017) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 115

Assessing dietary intake in the management of obesity

O'Neil, P. M. (2001) · Obesity Research

Nutrition, Health and Food BehaviorObesity, Physical Activity, Diet

Cited by 48